| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Departments of Medical Oncology (Drs. Logginidou and Henske) and Pathology (Drs. Ao and Russo), Fox Chase Cancer Center, Philadelphia, PA.
Correspondence to: Elizabeth Petri Henske, MD, Fox Chase Cancer Center, 7701 Burholme Ave, Philadelphia, PA 19111; e-mail EP_Henske@fccc.edu
Objective: To determine whether renal angiomyolipomas from women with pulmonary lymphangioleiomyomatosis (LAM) express estrogen receptor (ER) and progesterone receptor (PR).
Design: Retrospective study of archival tissue.
Patients: Twelve women with LAM and angiomyolipomas.
Setting: Fox Chase Cancer Center.
Interventions: ER and PR expression was studied using immunohistochemistry. The hormonal status of the patients at the time of resection of the angiomyolipoma was determined.
Results: Ten of the angiomyolipomas had ER immunoreactivity (83%), and all 12 had PR immunoreactivity (100%). The ER and PR positivity was in the smooth muscle component of the angiomyolipomas only. For five women, pulmonary LAM specimens were also available; two were ER positive (40%), and all five were PR positive (100%). All four angiomyolipomas from women receiving progesterone therapy were ER and PR positive. One tumor from a woman receiving tamoxifen was ER negative and strongly PR positive. One woman was pregnant; her tumor was ER and PR positive.
Conclusions: ER and PR expression is frequent in renal angiomyolipoma cells from women with LAM. PR was more consistently present than ER in angiomyolipomas and in LAM. Our data suggest that angiomyolipoma growth could be affected by hormonal factors. If the growth of LAM-associated angiomyolipomas slows during hormonal therapy, there are two potential implications for LAM patients: first, angiomyolipoma size could serve as a measurable indication of response to hormonal therapy; and second, surgical removal of angiomyolipomas might be avoided in some cases.
Key Words: angiomyolipoma • estrogen receptor • lymphangioleiomyomatosis • progesterone receptor • smooth muscle proliferation • tuberous sclerosis complex
This article has been cited by other articles:
|
|
 |
|
  J. H. Ryu, J. Moss, G. J. Beck, J.-C. Lee, K. K. Brown, J. T. Chapman, G. A. Finlay, E. J. Olson, S. J. Ruoss, J. R. Maurer, et al. The NHLBI Lymphangioleiomyomatosis Registry: Characteristics of 230 Patients at Enrollment Am. J. Respir. Crit. Care Med., January 1, 2006; 173(1): 105 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Yu, A. Astrinidis, S. Howard, and E. P. Henske Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways Am J Physiol Lung Cell Mol Physiol, April 1, 2004; 286(4): L694 - L700. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Yano Exacerbation of pulmonary lymphangioleiomyomatosis by exogenous oestrogen used for infertility treatment Thorax, December 1, 2002; 57(12): 1085 - 1086. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Dabbs, R. J. Landreneau, Y. Liu, S. S. Raab, R. H. Maley, M. Y. Tung, and J. F. Silverman Detection of estrogen receptor by immunohistochemistry in pulmonary adenocarcinoma Ann. Thorac. Surg., February 1, 2002; 73(2): 403 - 406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. STRIZHEVA, T. CARSILLO, W. D. KRUGER, E. J. SULLIVAN, J. H. RYU, and E. P. HENSKE The Spectrum of Mutations in TSC1 and TSC2 in Women with Tuberous Sclerosis and Lymphangiomyomatosis Am. J. Respir. Crit. Care Med., January 1, 2001; 163(1): 253 - 258. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. Carsillo, A. Astrinidis, and E. P. Henske Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis PNAS, May 23, 2000; 97(11): 6085 - 6090. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
